source
- Viatris to acquire Pacira BioSciences for $1.65 billion, adding two non-opioid pain drugsViatris announced Thursday it will purchase Pacira BioSciences for $1.65 billion in cash, paying $36.50 per share, a 45% premium to the prior close. The acquisition gives Viatris control of Pacira…
- FDA unveils transparency roadmap with plans for public NDA/BLA disclosures and inspection report publishingThe FDA published a transparency roadmap that outlines its FY 2026 achievements and sets out priorities for FY 2027. One key priority is a proposal to require public disclosure of new drug applica…